Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Feb 27

PMID 26918053

Citations 16

Authors

Mohamed Ben-Eltriki

Subrata Deb

Emma S Tomlinson Guns

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies indicate that vitamin D insufficiency could have an etiological role in prostate cancer. In addition, calcitriol, used in combination with currently available drugs, has the potential to potentiate their anticancer effects or act synergistically by inhibiting distinct mechanisms involved in prostate cancer growth. Clinical data have not yet provided sufficient evidence to demonstrate benefit of vitamin D due to the limited and underpowered studies that have been published to date. Here, we review the preclinical and clinical studies that describe the activity of calcitriol, applied either alone or in combination and assessed the mechanistic basis of pharmacodynamic and pharmacokinetic interactions with calcitriol. Important considerations for calcitriol use in combination therapy with respect to safety and clinical outcomes have been discussed. Many of these combinations have therapeutic potential for the treatment of several cancer types and it is anticipated that future clinical research will put emphasis on well‑designed clinical trials to establish efficacy.

Citing Articles

Target repositioning using multi-layer networks and machine learning: The case of prostate cancer.

Picard M, Scott-Boyer M, Bodein A, Leclercq M, Prunier J, Perin O Comput Struct Biotechnol J. 2024; 24:464-475.

PMID: 38983753 PMC: 11231507. DOI: 10.1016/j.csbj.2024.06.012.

Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.

Fendler A, Stephan C, Ralla B, Jung K Int J Mol Sci. 2024; 25(10).

PMID: 38791324 PMC: 11120741. DOI: 10.3390/ijms25105286.

Vitamin D in Melanoma: Potential Role of Cytochrome P450 Enzymes.

Ben-Eltriki M, Gayle E, Paras J, Nyame-Addo L, Chhabra M, Deb S Life (Basel). 2024; 14(4).

PMID: 38672780 PMC: 11050855. DOI: 10.3390/life14040510.

Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.

Lin M, Gong T, Ruan S, Lv X, Chen R, Su X J Inflamm Res. 2024; 17:2337-2351.

PMID: 38645875 PMC: 11032673. DOI: 10.2147/JIR.S454673.

Effect of calcium plus Vitamin-D combined with calcitriol in the treatment of patients with Type-2 diabetes and osteoporosis: A retrospective observational analysis.

Wan J, Xie J, Hu C, Liu J, Zhu C Pak J Med Sci. 2024; 40(3Part-II):444-448.

PMID: 38356827 PMC: 10862466. DOI: 10.12669/pjms.40.3.8795.

References

Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2002; 21(1):123-8. DOI: 10.1200/jco.2003.05.117. View

Trump D, Chadha M, Sunga A, Fakih M, Ashraf U, Silliman C . Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009; 104(7):909-14. PMC: 2889216. DOI: 10.1111/j.1464-410X.2009.08531.x. View

Srinivas S, Feldman D . A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009; 29(9):3605-10. View

Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y . Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr. 1998; 128(10):1710-5. DOI: 10.1093/jn/128.10.1710. View

Wu W, Zanello L, Walker A . S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Prostate. 2007; 67(14):1498-506. DOI: 10.1002/pros.20598. View

Thummel K, Wilkinson G . In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998; 38:389-430. DOI: 10.1146/annurev.pharmtox.38.1.389. View

Rashid S, Moore J, Walker E, Driver P, Engel J, Edwards C . Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 2001; 20(15):1860-72. DOI: 10.1038/sj.onc.1204269. View

Culig Z, Bartsch G, Hobisch A . Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol. 2002; 197(1-2):231-8. DOI: 10.1016/s0303-7207(02)00263-0. View

Chadha M, Tian L, Mashtare T, Payne V, Silliman C, Levine E . Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 2010; 116(9):2132-9. DOI: 10.1002/cncr.24973. View

10.

Mazaris E, Tsiotras A . Molecular pathways in prostate cancer. Nephrourol Mon. 2013; 5(3):792-800. PMC: 3830904. DOI: 10.5812/numonthly.9430. View

11.

Bhandari M, Crook J, Hussain M . Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol. 2005; 23(32):8212-8. DOI: 10.1200/JCO.2005.03.2557. View

12.

Raimondi S, Johansson H, Maisonneuve P, Gandini S . Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30(7):1170-80. DOI: 10.1093/carcin/bgp103. View

13.

Ly L, Zhao X, Holloway L, Feldman D . Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999; 140(5):2071-6. DOI: 10.1210/endo.140.5.6698. View

14.

Rochel N, Wurtz J, Mitschler A, Klaholz B, Moras D . The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000; 5(1):173-9. DOI: 10.1016/s1097-2765(00)80413-x. View

15.

Zhuang S, Schwartz G, Cameron D, Burnstein K . Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 1997; 126(1):83-90. DOI: 10.1016/s0303-7207(96)03974-3. View

16.

Morris H, Anderson P . Autocrine and paracrine actions of vitamin d. Clin Biochem Rev. 2010; 31(4):129-38. PMC: 2998276. View

17.

van Dodewaard-de Jong J, Verheul H, Bloemendal H, de Klerk J, Carducci M, van den Eertwegh A . New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. Clin Genitourin Cancer. 2015; 13(4):271-279. DOI: 10.1016/j.clgc.2015.01.008. View

18.

McMurtry J, Richards M, Brocht D . Serum corticosterone concentrations in developing shell-less and shelled turkey embryos. Comp Biochem Physiol A Comp Physiol. 1991; 100(1):135-7. DOI: 10.1016/0300-9629(91)90195-i. View

19.

Chen T, Holick M . Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003; 14(9):423-30. DOI: 10.1016/j.tem.2003.09.004. View

20.

Sha J, Pan J, Ping P, Xuan H, Li D, Bo J . Synergistic effect and mechanism of vitamin A and vitamin D on inducing apoptosis of prostate cancer cells. Mol Biol Rep. 2013; 40(4):2763-8. DOI: 10.1007/s11033-012-1925-0. View